Why Cutera's Shares Are Soaring Today

by Vandana Singh, Benzinga Editor

March 25, 2022 9:18 AM | 1 min read |

The FDA has granted 510(k) clearance to Cutera Inc's CUTR AviClear for acne.
The Company notes that AviClear is the first and only energy-based device to receive this designation to treat mild, moderate, and severe acne.
AviClear is a laser treatment that offers a safe, prescription-free solution for acne.
In addition to reducing existing acne, clinical trials show that future breakout episodes are shorter, less intense, and infrequent following the AviClear procedure.
Further, acne clearance results continue to improve over time, demonstrating the long-term efficacy of the treatment.
Significantly, no pain mitigation was utilized or required by any clinical study participant.
Price Action: CUTR shares are up 7.41% at $49.00 during the premarket session on the last check Friday

Posted In: News Health Care Small Cap FDA Movers Trading Ideas General Briefs why it's moving

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.